2024
Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies
Gu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.Peer-Reviewed Original ResearchInherited platelet disordersClinically significant bleedingCases of patientsHeterogeneous group of conditionsGroup of conditionsSignificant bleedingDiagnostic yieldDiagnostic dilemmaPlatelet disordersBleeding disordersEvaluating patientsPatient cohortMolecular pathogenesisMass cytometryHeterogeneous groupPatientsMultimodal approachBleedingImprove patient careDiagnosisDisordersPatient careGenetic sequencesLaboratory testing approachPotential utilityThrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review
Jacobs J, Sharma D, Stephens L, Villalba C, Rinder H, Woo J, Wheeler A, Gerberi D, Goel R, Tormey C, Booth G, Bloch E, Adkins B. Thrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review. British Journal Of Haematology 2024, 204: 1500-1506. PMID: 38291731, DOI: 10.1111/bjh.19313.Peer-Reviewed Original ResearchRisk of thrombosisHemoglobin C traitHemoglobin C diseaseVenous thromboembolismC diseaseIncreased risk of thrombosisProspective cohort studyFactor to thrombosisAssessment of patientsCohort studySystematic reviewInclusion criteriaPregnant individualsThrombotic riskCase seriesCase reportVTE riskChronic haemolysisSystematic literature reviewArterial thrombosisThrombosis riskHigh blood viscosityIncreased riskThrombosisC trait
2023
Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer
Burke O, Jacobs J, Tormey C, Rinder H, Villalba C, Lee E, Campos J, Abels E, Yurtsever N. Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer. Lab Medicine 2023, 55: 520-523. PMID: 38142129, DOI: 10.1093/labmed/lmad107.Peer-Reviewed Original ResearchNeuromyelitis optica spectrum disorderCreutzfeld-Jakob diseaseOptica spectrum disorderHeidenhain variantBilateral vision lossTherapeutic plasma exchangeReal-time quaking-induced conversionCreutzfeldt-Jakob diseaseImmunosuppressive therapyVisual disturbancesPlasma exchangeNeurocognitive symptomsTreatment modalitiesVision lossHospice careSpectrum disorderRare formPreliminary diagnosisDiseaseDiagnosisDisordersEarly stagesPatientsApheresisTherapyComprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test resultsMultimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders
Gu S, Gallagher P, Butt A, Gu V, Lezon-Geyda K, Schulz V, Prozora S, Lee A, Neparidze N, Bar N, Martin K, Cornell J, Chirico G, Chakraborty R, Rinder H, Hwa J, Bona R. Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders. Blood 2023, 142: 1197. DOI: 10.1182/blood-2023-177946.Peer-Reviewed Original ResearchBleeding tendencyBleeding disorderPlatelet markersPlatelet aggregometryMass cytometryPlatelet functionPlatelet disordersSingle-center prospective studyLow-risk groupAbnormal bleeding tendencyQualitative platelet disordersLarge patient cohortQuantitative platelet disordersCommon underlying causeGenetic variantsMultimodality evaluationTotal patientsRisk stratificationLaboratory suspicionPlatelet dysfunctionProspective studyPatient cohortUnivariate analysisPlatelet volumeRisk groupsBotulism mimicking Guillain‐Barre syndrome: The question of plasma exchange in an unusual case of acute paralysis
Campos J, Abels E, Rinder H, Tormey C, Jacobs J. Botulism mimicking Guillain‐Barre syndrome: The question of plasma exchange in an unusual case of acute paralysis. Journal Of Clinical Apheresis 2023, 38: 760-763. PMID: 37519071, DOI: 10.1002/jca.22081.Peer-Reviewed Original ResearchConceptsGuillain-Barré syndromeAcute flaccid paralysisFlaccid paralysisPlasma exchangeImmune-mediated polyradiculoneuropathyIntravenous immune globulinCranial nerve palsyGuillain-Barre syndromeCerebrospinal fluid analysisAppropriate therapeutic modalityCases of botulismAlbuminocytological dissociationNerve palsyRespiratory failureEmpiric administrationImmune globulinLaboratory featuresPrompt diagnosisIngestion/inhalationPoor outcomeAcute paralysisBotulinum toxinCommon causeTherapeutic modalitiesUnusual caseOptimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms
Puzo C, Tormey C, Rinder H, Siddon A. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transplantation And Cellular Therapy 2023, 29: 459.e1-459.e4. PMID: 37062510, DOI: 10.1016/j.jtct.2023.04.005.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationStem cell transplantationDonor chimerismCell transplantationNGS testingPost allogeneic stem cell transplantationMeasurable residual diseaseNext-generation sequencingAcute myeloid leukemiaConditioning regimenRelated donorsMyelodysplastic syndromeResidual diseaseValidation cohortMyeloid leukemiaMyeloid neoplasmsNGS panelLogistic regressionPatientsChimerismSignificant predictorsCharacteristic curveTransplantationRegimenConservative thresholdQuantitative Risk for Single-Positive Lupus Anticoagulant Results With Different Anticoagulants
Khan W, Tormey C, Rinder H, Siddon A. Quantitative Risk for Single-Positive Lupus Anticoagulant Results With Different Anticoagulants. American Journal Of Clinical Pathology 2023, 159: 417-419. PMID: 36940149, DOI: 10.1093/ajcp/aqac183.Peer-Reviewed Original Research
2022
Platelet production and kinetics
Binns T, Tormey C, Rinder H. Platelet production and kinetics. 2022, 158-167. DOI: 10.1002/9781119719809.ch15.ChaptersComplex biological processesPlatelet productionEpigenetic effectorsRegulatory RNAsMegakaryocyte differentiationPlatelet biogenesisAnucleate cellsGenetic regulationMatrix metalloproteinase proteinsNormal platelet productionMammalian physiologyTranscription factorsProplatelet processesSinusoidal blood vesselsBiological processesMature megakaryocytesMegakaryopoiesisMetalloproteinase proteinsMegakaryocytesHuman physiologyNew insightsEndothelial cellsTurnover rateNormal hemostasisPhysiologyA guide to molecular and functional investigations of platelets to bridge basic and clinical sciences
Tyagi T, Jain K, Gu S, Qiu M, Gu V, Melchinger H, Rinder H, Martin K, Gardiner E, Lee A, Tang W, Hwa J. A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences. Nature Cardiovascular Research 2022, 1: 223-237. PMID: 37502132, PMCID: PMC10373053, DOI: 10.1038/s44161-022-00021-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsVascular smooth muscle cellsPlatelet functional assaysCoronavirus disease 2019Smooth muscle cellsImmune cellsImmune regulationVascular remodelingDisease 2019Pathophysiological processesTranslational relevancePatient diagnosisFlow cytometryMuscle cellsPlatelet biologyFunctional assaysPlatelet investigationsHomeostatic processesPlateletsPhenotypic heterogeneityFunctional stateClinical scienceCellsAdditional roleThrombosisSuch diverse functions
2021
Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient
Jacobs JW, Gisriel SD, Iyer K, Rinder HM. Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient. Journal Of Thrombosis And Thrombolysis 2021, 53: 945-949. PMID: 34697688, PMCID: PMC8544916, DOI: 10.1007/s11239-021-02591-4.Peer-Reviewed Original ResearchConceptsPartial thromboplastin timeLupus anticoagulantFVIII inhibitorsAsymptomatic patientsFactor VIIIComprehensive hematologic evaluationLife-threatening hemorrhageTypical laboratory findingsDistinctive clinical presentationFactor VIII inhibitorsRisk of thrombosisSigns of hemorrhageSevere bleeding diathesisCoagulation factor VIIIImmunosuppressive therapyClinical presentationClinical symptomsPathologic antibodiesVIII inhibitorsLaboratory findingsHematologic evaluationUnique presentationBleeding diathesisThromboplastin timeAutoantibodies
2020
Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost
Gisriel S, Rinder H, Siddon A. Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost. Blood 2020, 136: 39-40. DOI: 10.1182/blood-2020-139035.Peer-Reviewed Original ResearchNext-generation sequencingNGS testingNGS testsAML/MDSEvidence-based indicationsPatients' emotional distressCancellation criteriaMedicaid Services reimbursementPersonalized patient careClinical suspicionPathologic diagnosisMedical recordsClinical indicationsClinical trialsChimerism statusUnnecessary testingMDS progressionPatient carePathogenic variantsMolecular findingsUnknown significancePatientsPathogenic mutationsService reimbursementMolecular diagnostic laboratoriesAssessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency
Gupta G, Hendrickson J, Bahel P, Siddon A, Rinder H, Tormey C. Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency. American Journal Of Clinical Pathology 2020, 154: s6-s7. DOI: 10.1093/ajcp/aqaa137.011.Peer-Reviewed Original ResearchAcute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis
Zanetto A, Rinder H, Deng Y, Ciarleglio M, Wilson F, Bulato C, Simioni P, Garcia-Tsao G. Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis. Digestive And Liver Disease 2020, 52: e13. DOI: 10.1016/j.dld.2019.12.031.Peer-Reviewed Original Research
2016
A Modified Approach to Fibrinogen Replacement in the Setting of Dysfibrinogenemia
Chandler J, Bahel P, Siddon A, Torres R, Rinder H, Tormey C. A Modified Approach to Fibrinogen Replacement in the Setting of Dysfibrinogenemia. American Journal Of Clinical Pathology 2016, 146: 326. DOI: 10.1093/ajcp/aqw160.005.Peer-Reviewed Original ResearchPlatelet production and kinetics
Tormey C, Rinder H. Platelet production and kinetics. 2016, 206-214. DOI: 10.1002/9781119013020.ch17.ChaptersDemarcation membrane systemPro-platelet formationPlatelet productionGenetic controlComplex pathwaysMegakaryocyte proliferationRegulationCurrent understandingMembrane systemNew insightsPlatelet lifespanBone marrowProductionMegakaryocytesPathwayStructural regulationMaturationProliferationLifespanUnderstanding
2015
Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia
Schulz W, Durant T, Rinder H, Tormey C, Torres R, Smith B, Hager K, Howe J, Siddon A. Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia. Blood 2015, 126: 1385. DOI: 10.1182/blood.v126.23.1385.1385.Peer-Reviewed Original ResearchDe novo acute myeloid leukemiaNovo acute myeloid leukemiaAcute myeloid leukemiaMolecular clonalityAML patientsTumor heterogeneityMyeloid leukemiaNext-generation sequencingNormal-risk subjectsAdverse prognostic indicatorTime of diagnosisFurther prospective studiesLong-term outcomesFLT3-ITD mutationHigh-risk groupChoice of therapyFirst prospective evidenceLimited clinical utilityHigh-risk classificationEarly survivalStudy patientsOverall survivalPatient agePatient subsetsInitial diagnosis
2013
Pathology Consultation on Evaluating Prognosis in Incidental Monoclonal Lymphocytosis and Chronic Lymphocytic Leukemia
Siddon AJ, Rinder HM. Pathology Consultation on Evaluating Prognosis in Incidental Monoclonal Lymphocytosis and Chronic Lymphocytic Leukemia. American Journal Of Clinical Pathology 2013, 139: 708-712. PMID: 23690112, DOI: 10.1309/ajcplir4gzwx3xka.Peer-Reviewed Original ResearchMeSH KeywordsADP-ribosyl Cyclase 1Beta 2-MicroglobulinFlow CytometryGene Rearrangement, B-LymphocyteHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionIncidental FindingsLeukemia, Lymphocytic, Chronic, B-CellLymphocytosisMaleMiddle AgedMutationPrognosisWatchful WaitingZAP-70 Protein-Tyrosine KinaseConceptsChronic lymphocytic leukemiaEarly-stage chronic lymphocytic leukemiaStage chronic lymphocytic leukemiaDisease progressionLymphocytic leukemiaImmunoglobulin heavy chain variable (IGHV) gene mutational statusMonoclonal B-cell lymphoproliferative disorderLaboratory evaluationOvert chronic lymphocytic leukemiaMonoclonal B-cell lymphocytosisB-cell lymphoproliferative disordersAggressive disease progressionSignificant disease progressionIndolent clinical courseSerum β2-microglobulinRoutine laboratory evaluationB-cell lymphocytosisZAP-70 expressionGene mutational statusMonoclonal lymphocytosisClinical courseExpectant observationLymphoproliferative disordersTherapeutic optionsPrognostic markerChapter 52 Cardiopulmonary Bypass
Smith B, Rinder H. Chapter 52 Cardiopulmonary Bypass. 2013, 1075-1096. DOI: 10.1016/b978-0-12-387837-3.00052-3.Peer-Reviewed Original ResearchChapter 62 Platelet Transfusion Medicine
Perrotta P, Parsons J, Rinder H, Snyder E. Chapter 62 Platelet Transfusion Medicine. 2013, 1275-1303. DOI: 10.1016/b978-0-12-387837-3.00062-6.Peer-Reviewed Original ResearchPlatelet transfusionsThrombocytopenic patientsTransfusion-related acute lung injuryTransfusion-transmitted viral infectionsAdverse effectsAcute lung injuryCommon adverse effectsPlatelet transfusion therapyLung injuryTransfusion therapyThrombocytopenic bleedingBlood therapyTransfusion reactionsBlood productsAllergic reactionsClinical experienceViral infectionTransfusionTransfusion medicineWhole bloodSeptic reactionsBleedingCell separatorPatientsTherapy